Blog Packaging Small Molecule 
Dark Matter Blog
APRIL 4, 2023
The bulk of my nearly three decades of experience up to that point was with drugging protein targets using a variety of modalities, but principally small molecules. The post Reinventing the small molecule toolbox: from proteins to RNA appeared first on Arrakis Therapeutics. As ever, we proceed fearlessly forward.
The Premier Consulting Blog
MAY 31, 2023
While the type, number, and design of these studies vary based on product-specific characteristics, IND-enabling packages submitted to the FDA generally include key information about the pharmacology, pharmacokinetics, and toxicology of the product. Primary pharmacology examines the on-target effects on the drug such as receptor binding.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Practical Cheminformatics
JANUARY 8, 2024
Gotta be SAFE: A New Framework for Molecular Design [link] A blog post by Edward Williams from Terray Therapeutics introduced Contrastive Optimization for Accelerated Therapeutic Inference (COATI). This novel embedding considers both the topological and three-dimensional structure of molecules. In this paper, the authors then used 1.1
FDA Law Blog: Biosimilars
MARCH 3, 2024
Conclusion Although the BIOSECURE Act has not been passed by Congress (or signed by the President), its sponsors are expected to push for its inclusion in the FY25 NDAA or as part of other omnibus legislative packages that arise this year.
Molecular Design
DECEMBER 31, 2023
The C2001 study (Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-α) is actually the more reference since it focuses of the nature of the photochemically enhanced binding. That concludes blogging for 2023 and many thanks to anybody who has read one of my posts.
Alta Sciences
NOVEMBER 5, 2024
Their advantages include ease of scalability and manufacturing, ease of packaging, and high product stability. This blog was originally posted 07/26/2021 and updated on 11/05/2024 Reference [link] Image Thumbnail_Blog-LFHSCs-alt.jpg Synopsis Liquid-filled capsules can be rapidly developed and tested, moving quickly from R&D to clinic.
The Premier Consulting Blog
SEPTEMBER 11, 2024
The 505(b)(2) new drug application (NDA) pathway offers a unique opportunity for small molecule developers to bring innovative products to market more efficiently by leveraging existing data they do not own or have right of reference to. The overall development strategy for GT123 was to include a complete CMC package.
Expert insights. Personalized for you.
52 
Let's personalize your content